Health and Welbeing
University of Miami initiates clinical trial of XM-ONEŽ
Friday, 08 June 2012
The transplantation unit at Jackson Memorial Hospital and the
University of Miami, FL, USA has entered into a research project with
the Allenex group company AbSorber. The project is a pilot study
evaluating the endothelial cell cross match XM-ONEŽ in their Living
Donor program. University of Miami will investigate if antibodies
detected by XM-ONEŽ will affect the outcome for the individual patient,
in pre- and post-transplant situations.
Corrected name: Dr Giselle Guerra. This news item sent first time June 7.
“Non-HLA antibodies, especially endothelial cell antibodies, play a
significant role as risk markers of acute rejection in kidney
transplant recipients” says Dr. Giselle Guerra, MD at the University of
Miami and principal investigator of the study. “However, the
post-transplant risk evaluation of these antibodies have not been
studied and we are excited to have this possibility”, she continues.
This prospective pilot study will include 138 patients and is estimated
to have an enrollment period of two years. Patients will thereafter be
monitored for six months post transplantation.
“The last years a number of researchers have published important data
on the relevance of non-HLA antibodies as well as XM-ONEŽ used for risk
assessment in a pre-transplant setting. An obvious next step is to
investigate the presence and importance of non-HLA antibodies
post-transplantation using XM-ONEŽ. We are proud that Dr. Guerra and
her co-workers at Jackson Memorial Hospital approached us to perform
this important study”, says Anders Karlsson, CEO of Allenex.
Based on a press release
Please leave a comment about the above article
